



IMMUNO-PROFILING™ SERVICES INCLUDE:

- Access to cutting edge immunological research methodologies
- The assurance of data security and study performance to agreed deadlines
- Bespoke experimental design to suit specific requirements
- Discussion and guidance from expert scientists prior to initiation of study and full discussion and interpretation of results



For further information or to discuss your company's needs without obligation please contact:


Dr Catherine Brady
 Chief Operating Officer
 Tel: +44 (0)121 414 8199
 Email: catherine.brady@celentyx.com
 Website: www.celentyx.com

Does your drug impact human Th17 immune cells?

Th17 cells: key players in autoimmune disease

Th17 cells are a specialised subpopulation of T helper cells that produce interleukin 17 and have been implicated in autoimmune diseases such as MS, psoriasis, autoimmune uveitis, diabetes, rheumatoid arthritis, and Crohn's disease.

Immuno-Profiling™ offers the ability to study the impact of a drug or biological on rare immune cell subsets such as Th17 cells from healthy donors or patients with relevant diseases



Example data: Impact of immunomodulator on the frequency of Th17 and Th1 cells shown as a % of vehicle (above) and representative FACS plots (below).

